Reading an FDA Complete Response Letter without panicking
What a CRL actually signals, the questions to ask next, and how the market routinely over-reacts.
Read on our blog →BullBearBio translates drug development, clinical evidence, and regulatory science into investor-ready insight, so you understand the asset before the catalyst, not after.
Most sites cover the news. We explain the science, the risk, and the value behind it, the three signals from our mark, turned into a method.
Mechanism of action, trial design, endpoints, and safety signals, read by people who actually understand the biology, not just the headline.
Clinical, regulatory, and dilution risk made explicit. Cash runway, burn rate, and probability-adjusted odds. The bear case stated plainly.
Market size, licensing deals, milestone payments, and a fair valuation range, so a 20 to 100% catalyst move never catches you blind.
We translate drug development, clinical evidence, and regulatory science into plain language. So you can see what stage a company is really at, what its pipeline can actually do, and whether the data supports the story — decisions built on evidence, not press releases. Free for everyone.
Clinical trial design and readouts decoded from primary registries and the literature.
The decisions that move stocks 20 to 100%, tracked across global agencies.
The mechanisms behind the modalities, explained without the jargon wall.
The metrics most retail investors never learn to read.
Who's ahead, which endpoint matters, and whether the mechanism is validated.
The data drops that reprice biotech overnight, previewed and analyzed.
Ten questions answered for every company we cover. From "does the science actually make sense?" to a defensible fair-value range and a clear investment conclusion — the depth of an analyst desk, written to be understood.
Browse Sample ReportsInteractive instruments that do the heavy analysis for you, the kind of edge that justifies a subscription.
Enter a company and trial, get a phase-success probability, plain-English endpoint explanation, and historical comparators.
Score any name across science, clinical data, regulatory position, financial strength, competition, and valuation.
Upcoming FDA decisions, Phase II/III readouts, and conference dates, every event that can reprice a stock, in one timeline.
Model burn rate against runway to see when, and how badly, a small-cap is likely to raise. Essential for micro-cap investors.
We help scientists and founders turn promising research into a fundable, partnerable proposition. Shaping the project, the evidence, and the story so retail investors and research organizations take it seriously.
We structure your project, milestones, and evidence so investors and grant committees see a credible, de-risked path to value.
We position your science for collaborations with research organizations, CROs, and academic groups — opening doors to non-dilutive funding.
We map the landscape to find the under-served niche where your technology has a durable, real-world edge.
A members' app that turns drug-development science into investor-ready intelligence. Search any biotech or pharma company for an AI-built report — price history, technology, graded clinical studies, financials and our BioStrength Index™ — then track a watchlist, compare conviction with the community, and earn by solving tasks for founders.
Generate a full AI report on any biotech stock, on demand. Real price history, mechanism of action, clinical studies graded by evidence, financial position and runway, plus a bull-vs-bear verdict — tailored to what you care about: pipeline, science, financials or competition.
Our proprietary 0–100 score for any company, set by our analysts. It weighs four pillars — technology precedent, clinical evidence, financial strength and team quality — into one number that shows whether the science, the balance sheet and the people line up.
A marketplace where founders post paid tasks and members earn by solving them. Budgets, due diligence, regulatory or scientific review — have the expertise? Make an offer, deliver, get paid. Building something? Get expert, AI-assisted help in one place.
Regular, free analysis on readouts, approvals, and the science that's actually moving biotech, written to be understood. No paywall.
What a CRL actually signals, the questions to ask next, and how the market routinely over-reacts.
Read on our blog →Effect size, endpoints, and the gap between a p-value and a commercial product.
Read on our blog →A jargon-free primer on the modality reshaping oncology, and where the science gets fragile.
Read on our blog →AI company reports, a personal watchlist, and paid tasks from biotech founders. Drop your email for the weekly catalyst briefing — or jump straight into the app.